"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.World Economyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Tensions between South Korea and Japan may ultimately disrupt the high-end tech sectors, says Heenam Choi, CEO at South Korea's sovereign wealth fund.Traderead more
On Sunday, the 71st Primetime Emmy Awards will honor the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
Gluskin Sheff's David Rosenberg reinforces his recession forecast following the Federal Reserve's September meeting.Futures Nowread more
The sharp drop-off in FDA warning letters for lies and misleading statements in ads in recent years, comes amid a 62 percent increase in direct-to-consumer ad spending by pharmaceutical companies, according to the New York Daily News, which first reported the record low.
Drugmakers now spend more than $6 billion annually on such ads.
In 2013, the FDA issued 24 warning letters to drugmakers, the Daily News reported. That fell to nine in 2014, with that same number again in 2015.
Last year, the drug regulatory agency sent out 11 letters.
But until mid-November of this year, the FDA had sent out just two warning letters.
The FDA warned Orexigen that the ad was misleading because it "fails to include important risk information associated with the drug," such as listing multiple conditions for which Contrave is contraindicated.
The second warning letter was sent in August to Cipher Pharmaceuticals for an ad for its extended-release opioid ConZip. The FDA said the ad had left out "important risk information associated with the use of ConZip and omits other material facts."
On Nov. 14, the FDA sent Amherst Pharmaceuticals a warning related to a webpage promoting the insomnia-treating medication Zolpimist.
"Both the webpage and the exhibit panels ... fail to communicate any risk information," the FDA said in its letter.
The agency went on to say the omission could "create a misleading impression about the drug's safety," which is "especially problematic from a public health perspective given the serious and potentially life-threatening risks associated with the drug."
In its story about the record low number of warning letters, the Daily News quoted a former FDA official who said the agency's Office of Prescription Drug Promotion — which monitors drug ads — is "a very, very small unit" that has "historically been underfunded."
CNBC asked the FDA about the report, and whether agency officials have been told to pull back on issuing warning letters this year.
FDA spokeswoman Stephanie Caccomo, in an emailed statement, said "Staff have not been instructed to avoid or reduce the number of enforcement letters issued to companies."
Caccomo added, "Issuing warning letters is just one component of the FDA's multi-faceted program" for overseeing promotion of medical products.
She said the agency uses "a risk-based approach to carefully allocate its resources among these activities to have the greatest beneficial public health impact."
"Therefore, one cannot get a complete picture of the FDA's program area by looking at a snapshot of time for warning letters," Caccomo said. "Reviewing the number of warning letters that the FDA issues on a particular topic within a year timeframe does not take into account the work that the FDA does on the other priorities to assist companies with compliance, such as policy and guidance development and core launch reviews, to fulfill its public health mission."